2022 Webinars Archives

We are Invivoscribe – Company Overview

2025-10-30T11:54:03-07:00December 30th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

Lab Secrets: The Potential for NGS-based MRD Testing for Acute Lymphoblastic Leukemia – The Austin Experience

2025-06-11T11:23:53-07:00November 15th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing

2025-12-30T15:46:07-08:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies

2025-06-11T08:54:09-07:00November 2nd, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination

2025-06-11T08:55:28-07:00October 26th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

A Comprehensive Solution for AML Precision Diagnostics

2025-06-11T08:57:05-07:00July 20th, 2022|2022 Videos, 2022 Webinars, Featured Videos, Videos|

Watch video

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

We are Invivoscribe – Company Overview

Lab Secrets: The Potential for NGS-based MRD Testing for Acute Lymphoblastic Leukemia – The Austin Experience

Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing

High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies

NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination

A Comprehensive Solution for AML Precision Diagnostics

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

We are Invivoscribe – Company Overview

Lab Secrets: The Potential for NGS-based MRD Testing for Acute Lymphoblastic Leukemia – The Austin Experience

Development and Implementation of an Automated and Highly Accurate Reporting Process for NGS-based Clonality Testing

High-Throughput Sequencing of TCR Gene Rearrangements as a Useful Tool for Identifying and Tracking Minimal/Measurable Residual Disease (MRD) in Lymphoid Malignancies

NGS-based Clinical Assessment of B- and T-cell Clonality and MRD Determination

A Comprehensive Solution for AML Precision Diagnostics

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.